INTRODUCTION {#s1}
============

Gram-negative pathogens causing serious infections are becoming an increasing clinical concern ([@B1][@B2][@B5]). Important antimicrobial-resistant Gram-negative pathogens include extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae; carbapenemase-producing, fluoroquinolone-resistant, and multidrug-resistant (MDR) *Enterobacterales*; as well as carbapenem-resistant and MDR Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia ([@B1][@B2][@B5]). In fact, many of these pathogens have recently been highlighted among Gram-negative MDR pathogens classified as urgent/critical or serious/high public health threats by the Centers for Disease Control and Prevention (CDC) ([@B1]) and the World Health Organization (WHO) ([@B6]).

Eravacycline is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of serious infections, including those caused by MDR pathogens ([@B5], [@B7]; <https://clinicaltrials.gov/ct2/show/NCT01844856>). Eravacycline is comprised of a tetracycline core with two novel modifications, a fluorine atom at the C-7 position and a pyrrolidinoacetamido group at the C-9 position, both of which are on the D ring ([@B7], [@B9]). These novel modifications confer enhanced *in vitro* activity compared to that of other tetracyclines against resistant Gram-negative and Gram-positive bacteria, and the pyrrolidinoacetamido group allows for increased ribosomal binding and steric hindrance to avoid ribosome protection-based tetracycline resistance.

Eravacycline inhibits bacterial protein synthesis (i.e., acyl-tRNA transfer) by binding to the 30S ribosomal subunit ([@B10]). Eravacycline demonstrates potent broad-spectrum activity against Gram-negative bacilli (except for P. aeruginosa and *Burkholderia* spp.) and Gram-positive cocci, including anaerobes, as well as atypical bacterial pathogens and Neisseria gonorrhoeae ([@B5], [@B11][@B12][@B16]), and does not exhibit a loss of antibacterial activity against isolates expressing tetracycline ribosomal protection genes or most tetracycline efflux resistance genes ([@B10], [@B11], [@B14]).

Eravacycline has successfully completed clinical trials for the treatment of complicated intra-abdominal infection (cIAI) (<https://clinicaltrials.gov/ct2/show/NCT01844856>) and has been approved for use by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, eravacycline has demonstrated *in vivo* efficacy as a treatment in murine models of systemic, thigh, and lung infection and pyelonephritis.

The objective of the current study was to determine the *in vitro* activity of eravacycline relative to that of other antimicrobial agents using a representative global collection of clinical isolates of Gram-negative bacilli.

RESULTS AND DISCUSSION {#s2}
======================

A total of 17,781 Gram-negative aerobic isolates collected between 2013 and 2017 were included in this study. *Enterobacteriaceae* accounted for the majority of these isolates (*n* = 10,531). The MIC distributions for these isolates and the cumulative percentage of isolates inhibited by eravacycline are shown in [Table 1](#T1){ref-type="table"}. The MIC~90~ for isolates of A. baumannii was 1 μg/ml, and it was 0.5 μg/ml for the four genera/species of *Enterobacteriaceae* combined and 2 μg/ml for S. maltophilia. Among the six genera/species of *Enterobacterales* tested, MIC~90~ values were as follows: E. coli, 0.25 μg/ml; *Klebsiella* spp. and *Citrobacter* spp., 0.5 μg/ml; *Enterobacter* spp., 1 μg/ml; and Proteus mirabilis and Serratia marcescens, 2 μg/ml. For MDR populations of these organisms, the MIC~90~ values of eravacycline remained within 2- to 4-fold of the MIC~90~s indicated above. Given eravacycline's limited activity against P. aeruginosa ([Table 1](#T1){ref-type="table"}), concordant with this pathogen's established intrinsic resistance to tetracyclines, it was excluded from further analyses ([@B17]).

###### 

Cumulative percentage of all clinical isolates of *Enterobacteriaceae*, individual genera/species of *Enterobacterales*, A. baumannii, P. aeruginosa, and S. maltophilia tested from 2013 to 2017 inhibited by eravacycline, by MIC

  Organism                                          No. of isolates   Cumulative % of isolates inhibited by eravacycline at the following MIC (μg/ml)[^*a*^](#T1F1){ref-type="table-fn"}:                                                                              
  ------------------------------------------------- ----------------- --------------------------------------------------------------------------------------------------------------------- ------- ------- ------ ------ ------ ------- ------ ------ -------- ------ -----
  All isolates                                                                                                                                                                                                                                                         
      *Enterobacteriaceae*                          10,531                                                                                                                                  \<0.1   2.4%    30.0   73.2   92.6   96.9    98.9   99.8   \>99.9   100    
      *Klebsiella* spp.                             4,965                                                                                                                                           0.7     23.2   73.0   90.6   95.8    98.6   99.7   \>99.9   100    
      *Enterobacter* spp.                           1,820                                                                                                                                           \<0.1   3.0    43.1   89.6   95.5    98.0   99.7   100             
      *Citrobacter* spp.                            1,776                                                                                                                                           1.0     37.4   81.9   94.6   98.3    99.8   100                    
      E. coli                                       1,970                                                                                                                                   0.2     9.9     65.4   94.0   98.8   99.7    100                           
      P. mirabilis                                  1,348                                                                                                                                                   0.1    1.4    10.6   48.3    91.8   99.6   99.8     99.9   100
      S. marcescens                                 948                                                                                                                                                     0.1    0.6    10.3   67.1    95.6   99.3   100             
      A. baumannii                                  2,097             1.0                                                                                                                   7.3     18.4    28.9   42.3   70.5   92.5    98.7   99.6   99.9     100    
      P. aeruginosa                                 1,647                                                                                                                                   0.1             0.2    0.3    1.0    2.9     6.7    37.2   78.2     96.6   100
      S. maltophilia                                1,210                                                                                                                                   0.1     0.4     2.8    13.5   41.7   77.9    93.6   98.9   99.9     100    
  MDR isolates[^*b*^](#T1F2){ref-type="table-fn"}                                                                                                                                                                                                                      
      *Enterobacteriaceae*                          2,051                                                                                                                                   \<0.1   1.5     18.3   55.0   80.5   91.3%   96.8   99.5   \>99.9   100    
      *Klebsiella* spp.                             801                                                                                                                                             0.4     8.5    43.7   72.4   88.0    95.1   99.0   99.9     100    
      *Enterobacter* spp.                           448                                                                                                                                                     1.6    32.6   73.4   86.4    94.4   99.3   100             
      *Citrobacter* spp.                            247                                                                                                                                             0.4     17.4   55.5   80.2   91.9    99.2   100                    
   E. coli                                          555                                                                                                                                     0.2     4.7     46.5   89.2   98.0   99.6    100                           
   P. mirabilis                                     328                                                                                                                                                            0.6    7.9    37.5    82.9   98.8   99.1     99.7   100
   S. marcescens                                    87                                                                                                                                                                    4.6    43.7    86.2   97.7   100             
   A. baumannii                                     1,502                                                                                                                                   0.1     1.4     7.4    21.5   59.1   89.5    98.1   99.4   99.9     100    
   P. aeruginosa                                    339                                                                                                                                                                   0.3    3.2     6.2    21.2   56.0     90.6   100
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The MIC~90~ is shaded gray.

MDR was defined using CLSI breakpoints.

When isolates were allocated to their respective geographic regions, eravacycline MIC~50~s and MIC~90~s were within 1 doubling dilution for all *Enterobacteriaceae* combined, individual genera/species of *Enterobacterales*, A. baumannii, and S. maltophilia (see Table S1 in the supplemental material). Similarly, there were no significant differences (a \>1-doubling-dilution increase or decrease in the MIC~50~s or MIC~90~s) observed in the *in vitro* activity of eravacycline for any genera/species of Gram-negative bacilli stratified by specimen source (Table S2) or stratified by study period (2013 to 2014, 2015, 2016, 2017) (Table S3). A detailed trend analysis could not be conducted, given that there were changes in participating laboratories and the panel of antimicrobial agents tested over the time period studied (2013 to 2017).

The *in vitro* activities of eravacycline and comparator agents against *Enterobacterales*, A. baumannii, and S. maltophilia isolates and their MDR counterparts are shown in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively. The rates of susceptibility of *Enterobacteriaceae* spp. to eravacycline were high, with the susceptibility rates being 98.8% for E. coli, 90.6% for *Klebsiella* spp., 94.6% for *Citrobacter* spp., and 89.6% for *Enterobacter* spp. ([Table 2](#T2){ref-type="table"}) ([@B18]). For MDR organisms, the rates of susceptibility to eravacycline for E. coli remained high (97.5%) and ranged from 77 to 81.9% for the other *Enterobacteriaceae* ([Table 3](#T3){ref-type="table"}). Breakpoint interpretations were not available for eravacycline against the other organisms tested.

###### 

*In vitro* activity of eravacycline and comparator agents against *Enterobacteriaceae*, individual genera/species of *Enterobacterales*, A. baumannii, and S. maltophilia, cumulative 2013 to 2017 data

  Organism               Antimicrobial agent             No. of isolates   MIC (μg/ml)   \% susceptible according to the following breakpoint:                                                              
  ---------------------- ------------------------------- ----------------- ------------- ------------------------------------------------------- ---------------- ----------------------------------------- ---------------------------------------
  *Enterobacteriaceae*   Eravacycline                    10,531            0.25          0.5                                                     0.03 to 16       92.6[^*a*^](#T2F1){ref-type="table-fn"}   92.6
                         Amikacin                        7,534             1             4                                                       ≤0.25 to \>64    99.1                                      98.3
                         Aztreonam                       10,531            0.25          \>16                                                    ≤0.03 to \>16    78.9                                      76.2
                         Cefepime                        10,531            0.12          8                                                       ≤0.008 to \>16   87.9                                      85.5
                         Cefotaxime                      7,534             0.12          \>64                                                    ≤0.015 to \>64   76.2                                      76.2
                         Ceftazidime                     10,531            ≤0.5          32                                                      ≤0.5 to \>16     80.1                                      76.9
                         Ceftriaxone                     10,531            0.25          \>4                                                     ≤0.5 to \>4      76.4                                      76.4
                         Colistin                        10,531            0.5           1                                                       ≤0.12 to \>4     NA[^*c*^](#T2F3){ref-type="table-fn"}     99.4
                         Ertapenem                       7,534             0.015         0.25                                                    ≤0.002 to \>2    94.2                                      94.2
                         Gentamicin                      10,531            0.5           2                                                       ≤0.25 to \>8     91.2                                      90.7
                         Imipenem                        2,997             0.5           2                                                       ≤0.25 to \>8     86.7                                      97.5
                         Levofloxacin                    10,531            0.12          \>4                                                     ≤0.25 to \>4     82.4                                      82.4
                         Meropenem                       7,534             0.03          0.06                                                    ≤0.004 to \>4    97.9                                      98.2
                         Minocycline                     5,059             2             8                                                       ≤0.12 to \>16    84.0                                      NA
                         Piperacillin-tazobactam         10,531            2             64                                                      ≤0.5 to \>64     84.3                                      79.9
                         Tetracycline                    10,531            2             64                                                      ≤0.25 to \>8     80.3                                      NA
                         Tigecycline                     10,531            0.5           1                                                       ≤0.015 to 32     96.8[^*a*^](#T2F1){ref-type="table-fn"}   70.6
                         Trimethoprim-sulfamethoxazole   7,534             0.12          \>4                                                     ≤0.06 to \>4     81.5                                      81.5
  *Klebsiella* spp.      Eravacycline                    4,965             0.25          0.5                                                     0.06 to 16       90.6                                      90.6
                         Amikacin                        3,472             1             2                                                       ≤0.25 to \>64    98.5                                      97.8
                         Aztreonam                       4,965             ≤0.5          \>16                                                    ≤0.5 to \>16     80.5                                      77.6
                         Cefepime                        4,965             ≤0.25         8                                                       ≤0.25 to \>16    88.7                                      87.4
                         Cefotaxime                      3,472             0.06          \>64                                                    ≤0.015 to \>64   78.9                                      78.9
                         Ceftazidime                     4,965             ≤0.5          \>16                                                    ≤0.5 to \>16     82.4                                      79.4
                         Ceftriaxone                     4,965             ≤0.5          \>4                                                     ≤0.5 to \>4      78.4                                      78.4
                         Colistin                        1,493             0.5           1                                                       ≤0.12 to \>4     NA                                        98.2
                         Ertapenem                       3,472             0.015         0.25                                                    ≤0.002 to \>2    94.7                                      94.7
                         Gentamicin                      4,965             ≤0.25         1                                                       ≤0.25 to \>8     92.6                                      92.3
                         Imipenem                        1,493             0.5           2                                                       ≤0.25 to \>8     81.0                                      96.3
                         Levofloxacin                    4,965             ≤0.25         2                                                       ≤0.25 to \>4     85.7                                      85.7
                         Meropenem                       3,472             0.03          0.06                                                    ≤0.004 to \>4    96.7                                      97.0
                         Minocycline                     2,324             2             8                                                       ≤0.12 to \>16    83.3                                      NA
                         Piperacillin-tazobactam         4,965             2             64                                                      ≤0.5 to \>64     83.3                                      79.2
                         Tetracycline                    4,965             2             \>8                                                     ≤0.25 to \>8     84.1                                      NA
                         Tigecycline                     4,965             0.5           2                                                       0.06 to 32       95.9                                      64.1
                         Trimethoprim-sulfamethoxazole   3,472             0.12          \>4                                                     ≤0.06 to \>4     86.0                                      86.0
  *Enterobacter* spp.    Eravacycline                    1,820             0.5           1                                                       0.06 to 8        89.6                                      89.6
                         Amikacin                        1,322             1             2                                                       ≤0.25 to \>64    99.4                                      98.8
                         Aztreonam                       1,820             ≤0.5          \>16                                                    ≤0.5 to \>16     68.6                                      66.0
                         Cefepime                        1,820             ≤0.25         8                                                       ≤0.25 to \>16    84.6                                      79.0
                         Cefotaxime                      1,322             0.5           \>64                                                    ≤0.015 to \>64   63.2                                      63.2
                         Ceftazidime                     1,820             ≤0.5          \>16                                                    ≤0.5 to \>16     67.9                                      65.1
                         Ceftriaxone                     1,820             ≤0.5          \>4                                                     ≤0.5 to \>4      63.7                                      63.7
                         Colistin                        498               0.5           1                                                       ≤0.12 to \>4     NA                                        94.4
                         Ertapenem                       1,322             0.06          1                                                       0.004 to \>2     86.4                                      86.4
                         Gentamicin                      1,820             ≤0.25         2                                                       ≤0.25 to \>8     91.2                                      90.3
                         Imipenem                        498               0.5           1                                                       ≤0.25 to \>8     91.6                                      97.2
                         Levofloxacin                    1,820             ≤0.25         1                                                       ≤0.25 to \>4     87.1                                      87.1
                         Meropenem                       1,322             0.06          0.12                                                    0.008 to \>4     98.3                                      98.8
                         Minocycline                     880               4             8                                                       0.25 to \>16     83.4                                      NA
                         Piperacillin-tazobactam         1,820             4             \>64                                                    ≤0.5 to \>64     76.2                                      71.0
                         Tetracycline                    1,820             2             \>8                                                     0.5 to \>8       83.8                                      NA
                         Tigecycline                     1,820             0.5           2                                                       0.03 to 8        95.5                                      55.9
                         Trimethoprim-sulfamethoxazole   1,322             0.12          \>4                                                     ≤0.06 to \>4     82.6                                      82.6
  *Citrobacter* spp.     Eravacycline                    1,776             0.25          0.5                                                     0.06 to 4        94.6                                      94.6
                         Amikacin                        1,272             1             2                                                       ≤0.25 to \>64    99.6                                      99.0
                         Aztreonam                       1,776             ≤0.5          \>16                                                    ≤0.5 to \>16     82.3                                      80.2
                         Cefepime                        1,776             ≤0.25         1                                                       ≤0.25 to \>16    94.8                                      91.5
                         Cefotaxime                      1,272             0.12          64                                                      ≤0.015 to \>64   79.5                                      79.5
                         Ceftazidime                     1,776             ≤0.5          \>16                                                    ≤0.5 to \>16     82.0                                      79.1
                         Ceftriaxone                     1,776             ≤0.5          \>4                                                     ≤0.5 to \>4      80.6                                      80.6
                         Colistin                        504               1             1                                                       ≤0.12 to \>4     NA                                        99.0
                         Ertapenem                       1,272             0.008         0.25                                                    ≤0.002 to \>2    96.1                                      96.1
                         Gentamicin                      1,776             0.5           1                                                       ≤0.25 to \>8     95.7                                      95.4
                         Imipenem                        504               0.5           2                                                       ≤0.25 to \>8     86.7                                      98.8
                         Levofloxacin                    1,776             ≤0.25         0.5                                                     ≤0.25 to \>4     90.0                                      90.0
                         Meropenem                       1,272             0.03          0.06                                                    0.008 to \>4     98.7                                      98.7
                         Minocycline                     881               2             8                                                       ≤0.12 to \>16    87.2                                      NA
                         Piperacillin-tazobactam         1,776             2             64                                                      ≤0.5 to \>64     86.0                                      81.2
                         Tetracycline                    1,776             1             8                                                       ≤0.25 to \>8     89.3                                      NA
                         Tigecycline                     1,776             0.5           1                                                       ≤0.015 to 4      97.8                                      80.5
                         Trimethoprim-sulfamethoxazole   1,272             ≤0.06         1                                                       ≤0.06 to \>4     90.4                                      90.4
  E. coli                Eravacycline                    1,970             0.12          0.25                                                    0.03 to 2        98.8                                      98.8
                         Amikacin                        1,468             2             4                                                       ≤0.25 to \>64    99.7                                      98.5
                         Aztreonam                       1,970             ≤0.5          \>16                                                    ≤0.5 to \>16     81.5                                      78.5
                         Cefepime                        1,970             ≤0.25         \>16                                                    ≤0.25 to \>16    82.8                                      81.5
                         Cefotaxime                      1,468             0.06          \>64                                                    ≤0.015 to \>64   78.7                                      78.7
                         Ceftazidime                     1,970             ≤0.5          16                                                      ≤0.5 to \>16     84.2                                      79.8
                         Ceftriaxone                     1,970             ≤0.5          \>4                                                     ≤0.5 to \>4      79.6                                      79.6
                         Colistin                        502               0.5           1                                                       0.25 to 4        NA                                        99.4
                         Ertapenem                       1,468             0.008         0.06                                                    ≤0.002 to \>2    98.7                                      98.7
                         Gentamicin                      1,970             0.5           \>8                                                     ≤0.25 to \>8     83.5                                      82.8
                         Imipenem                        502               ≤0.25         0.5                                                     ≤0.25 to 2       99.0                                      100.0
                         Levofloxacin                    1,970             ≤0.25         \>4                                                     ≤0.25 to \>4     62.8                                      62.8
                         Meropenem                       1,468             0.03          0.03                                                    ≤0.004 to 2      99.7                                      100.0
                         Minocycline                     974               1             16                                                      ≤0.12 to \>16    83.5                                      NA
                         Piperacillin-tazobactam         1,970             2             16                                                      ≤0.5 to \>64     92.5                                      88.9
                         Tetracycline                    1,970             2             \>8                                                     ≤0.25 to \>8     59.4                                      NA
                         Tigecycline                     1,970             0.25          0.5                                                     0.03 to 4        99.2                                      91.6
                         Trimethoprim-sulfamethoxazole   1,468             0.12          \>4                                                     ≤0.06 to \>4     62.3                                      62.3
  P. mirabilis           Eravacycline                    1,348             2             2                                                       0.12 to \>16     10.6                                      10.6
                         Amikacin                        940               2             4                                                       0.5 to \>64      97.8                                      96.7
                         Aztreonam                       1,348             ≤0.5          ≤0.5                                                    ≤0.5 to \>16     98.6                                      94.6
                         Cefepime                        1,348             ≤0.25         1                                                       ≤0.25 to \>16    94.2                                      92.2
                         Cefotaxime                      940               ≤0.015        2                                                       ≤0.015 to \>64   89.4                                      89.4
                         Ceftazidime                     1,348             ≤0.5          ≤0.5                                                    ≤0.5 to \>16     94.4                                      91.8
                         Ceftriaxone                     1,348             ≤0.5          2                                                       ≤0.5 to \>4      89.9                                      89.9
                         Colistin                        408               \>4           \>4                                                     4 to \>4         NA                                        0.0
                         Ertapenem                       940               0.015         0.015                                                   0.004 to \>2     99.7                                      99.7
                         Gentamicin                      1,348             1             \>8                                                     ≤0.25 to \>8     84.9                                      79.1
                         Imipenem                        408               2             4                                                       ≤0.25 to \>8     19.1                                      NA[^*b*^](#T2F2){ref-type="table-fn"}
                         Levofloxacin                    1,348             ≤0.25         \>4                                                     ≤0.25 to \>4     67.6                                      67.6
                         Meropenem                       940               0.06          0.12                                                    0.008 to \>4     99.7                                      99.8
                         Minocycline                     631               16            \>16                                                    1 to \>16        2.2                                       NA
                         Piperacillin-tazobactam         1,348             ≤0.5          1                                                       ≤0.5 to \>64     98.8                                      98.0
                         Tetracycline                    1,348             \>8           \>8                                                     0.5 to \>8       2.0                                       NA
                         Tigecycline                     1,348             4             8                                                       0.25 to \>32     26.7                                      1.3
                         Trimethoprim-sulfamethoxazole   940               0.12          \>4                                                     ≤0.06 to \>4     64.2                                      64.2
  S. marcescens          Eravacycline                    948               1             2                                                       0.12 to 8        10.3                                      10.3
                         Amikacin                        451               2             4                                                       ≤0.25 to \>64    98.9                                      97.8
                         Aztreonam                       948               ≤0.5          2                                                       ≤0.5 to \>16     92.7                                      89.6
                         Cefepime                        948               ≤0.25         0.5                                                     ≤0.25 to \>16    95.5                                      94.4
                         Cefotaxime                      451               0.5           8                                                       0.06 to \>64     81.2                                      81.2
                         Ceftazidime                     948               ≤0.5          1                                                       ≤0.5 to \>16     95.9                                      93.0
                         Ceftriaxone                     948               ≤0.5          4                                                       ≤0.5 to \>4      87.1                                      87.1
                         Colistin                        497               \>4           \>4                                                     1 to \>4         NA                                        3.8
                         Ertapenem                       451               0.03          0.12                                                    0.008 to \>2     95.8                                      95.8
                         Gentamicin                      948               0.5           2                                                       ≤0.25 to \>8     96.3                                      94.8
                         Imipenem                        497               1             2                                                       ≤0.25 to \>8     88.1                                      98.6
                         Levofloxacin                    948               ≤0.25         2                                                       ≤0.25 to \>4     85.2                                      85.2
                         Meropenem                       451               0.06          0.12                                                    0.008 to \>4     97.1                                      97.1
                         Minocycline                     229               4             8                                                       0.5 to \>16      85.2                                      NA
                         Piperacillin-tazobactam         948               2             16                                                      ≤0.5 to \>64     91.6                                      87.7
                         Tetracycline                    948               \>8           \>8                                                     2 to \>8         3.2                                       NA
                         Tigecycline                     948               2             2                                                       0.25 to 16       92.2                                      2.9
                         Trimethoprim-sulfamethoxazole   451               0.25          1                                                       ≤0.06 to \>4     93.4                                      93.4
  A. baumannii           Eravacycline                    2,097             0.5           1                                                       ≤0.015 to 16     NA                                        NA
                         Amikacin                        1,598             32            \>64                                                    0.12 to \>64     48.9                                      46.5
                         Ampicillin-sulbactam            1,598             32            \>64                                                    0.25 to \>64     33.1                                      NA
                         Aztreonam                       2,097             \>16          \>16                                                    ≤0.03 to \>16    NA                                        NA
                         Cefepime                        2,097             \>16          \>16                                                    ≤0.25 to \>16    27.6                                      NA
                         Ceftazidime                     2,097             \>16          \>16                                                    ≤0.5 to \>16     30.2                                      NA
                         Ceftriaxone                     2,097             \>32          \>32                                                    ≤0.03 to \>32    12.7                                      NA
                         Colistin                        2,097             0.5           2                                                       ≤0.03 to \>4     95.1                                      95.1
                         Gentamicin                      2,097             \>8           \>8                                                     ≤0.03 to \>8     38.9                                      38.9
                         Imipenem                        499               \>8           \>8                                                     ≤0.25 to \>8     37.3                                      37.3
                         Levofloxacin                    2,097             \>4           \>4                                                     ≤0.25 to \>4     27.7                                      26.1
                         Meropenem                       1,598             32            \>64                                                    ≤0.03 to \>64    33.9                                      33.9
                         Minocycline                     1,598             2             16                                                      ≤0.03 to \>64    67.3                                      NA
                         Piperacillin-tazobactam         2,097             \>64          \>64                                                    ≤0.5 to \>64     25.9                                      NA
                         Tetracycline                    2,097             \>8           \>8                                                     ≤0.25 to \>8     26.8                                      NA
                         Tigecycline                     2,097             2             4                                                       0.06 to \>16     NA                                        NA
                         Trimethoprim-sulfamethoxazole   1,598             16            \>64                                                    ≤0.03 to \>64    39.3                                      39.3
  S. maltophilia         Eravacycline                    1,210             1             2                                                       0.03 to 16       NA                                        NA
                         Amikacin                        1,080             \>64          \>64                                                    0.12 to \>64     NA                                        NA
                         Ampicillin-sulbactam            1,080             \>64          \>64                                                    1 to \>64        NA                                        NA
                         Aztreonam                       1,210             \>16          \>16                                                    0.06 to \>16     NA                                        NA
                         Cefepime                        1,210             \>16          \>16                                                    0.06 to \>16     NA                                        NA
                         Ceftazidime                     1,210             16            \>16                                                    ≤0.5 to \>16     39.2                                      NA
                         Ceftriaxone                     1,210             \>32          \>32                                                    0.12 to \>32     NA                                        NA
                         Colistin                        1,210             2             \>4                                                     ≤0.12 to \>4     NA                                        NA
                         Gentamicin                      1,210             \>8           \>8                                                     ≤0.25 to \>8     NA                                        NA
                         Imipenem                        130               \>8           \>8                                                     4 to \>8         NA                                        NA
                         Levofloxacin                    1,210             1             \>4                                                     ≤0.25 to \>4     76.4                                      NA
                         Meropenem                       1,080             \>64          \>64                                                    0.06 to \>64     NA                                        NA
                         Minocycline                     1,080             0.5           2                                                       0.06 to 64       99.0                                      NA
                         Piperacillin-tazobactam         1,210             \>64          \>64                                                    2 to \>64        NA                                        NA
                         Tetracycline                    1,210             \>8           \>8                                                     1 to \>8         NA                                        NA
                         Tigecycline                     1,210             2             4                                                       0.06 to \>16     NA                                        NA
                         Trimethoprim-sulfamethoxazole   1,080             0.5           4                                                       ≤0.03 to \>64    84.3                                      90.3

![](AAC.01699-19-t0002)

U.S. Food and Drug Administration (FDA) MIC interpretative breakpoints for *Enterobacteriaceae* for eravacycline (susceptible, ≤0.5 μg/ml) and tigecycline (susceptible, ≤2 μg/ml; intermediate, 4 μg/ml; resistant, ≥8 μg/ml) ([@B20]) were used in place of CLSI MIC breakpoints, as none currently exist. The 2019 EUCAST MIC interpretative breakpoints for tigecycline (susceptible, ≤0.5 μg/ml; resistant, ≥1 μg/ml) ([@B19]) are different from the FDA MIC breakpoints.

The MIC panel range is not low enough for *Proteeae* for 2019 EUCAST breakpoints.

NA, MIC breakpoint not available.

###### 

*In vitro* activity of eravacycline and comparator agents against MDR *Enterobacteriaceae*, individual genera/species of *Enterobacterales*, and A. baumannii, cumulative 2013 to 2017 data

  Organism                   Antimicrobial agent             CLSI criteria   EUCAST criteria                                                                                                              
  -------------------------- ------------------------------- --------------- ----------------- ------ ---------------- ----------------------------------------- ------- ------- ------- ---------------- -----------------------------------------
  All *Enterobacteriaceae*   Eravacycline                    2,051           0.25              1      0.03 to 16       80.5[^*a*^](#T3F1){ref-type="table-fn"}   2,186   0.25    1       0.06 to 16       82.0[^*b*^](#T3F2){ref-type="table-fn"}
                             Amikacin                        1,656           2                 8      ≤0.25 to \>64    96.0                                      1,614   2       8       ≤0.25 to \>64    92.5
                             Aztreonam                       2,051           \>16              \>16   ≤0.5 to \>16     18.4                                      2,186   \>16    \>16    ≤0.03 to \>16    6.2
                             Cefepime                        2,051           4                 \>16   ≤0.25 to \>16    42.1                                      2,186   4       \>16    0.015 to \>16    35.3
                             Cefotaxime                      1,656           \>64              \>64   ≤0.015 to \>64   17.5                                      1,614   \>64    \>64    ≤0.015 to \>64   8.1
                             Ceftazidime                     2,051           \>16              \>16   ≤0.5 to \>16     24.3                                      2,186   32      \>16    ≤0.03 to \>16    9.0
                             Ceftriaxone                     2,051           \>4               \>4    ≤0.5 to \>4      14.7                                      2,186   \>4     \>4     ≤0.015 to \>4    6.0
                             Colistin                        2,051           0.5               1      ≤0.12 to \>4     NA[^*c*^](#T3F3){ref-type="table-fn"}     2,186   0.5     1       ≤0.12 to \>4     98.7
                             Ertapenem                       1,656           0.12              \>2    0.004 to \>2     75.7                                      1,614   0.25    \>2     0.004 to \>2     73.9
                             Gentamicin                      2,051           1                 \>8    ≤0.25 to \>8     58.6                                      2,186   1       \>8     ≤0.12 to \>8     62.1
                             Imipenem                        395             0.5               8      ≤0.25 to \>8     76.0                                      572     0.5     2       ≤0.25 to \>8     90.4
                             Levofloxacin                    2,051           4                 \>4    ≤0.25 to \>4     34.8                                      2,186   2       \>8     0.008 to \>4     43.4
                             Meropenem                       1,656           0.06              1      ≤0.004 to \>4    90.7                                      1,614   0.06    1       ≤0.004 to \>4    91.6
                             Minocycline                     1,112           4                 \>16   ≤0.12 to \>16    58.0                                      1,166   4       \>16    ≤0.12 to \>16    NA
                             Piperacillin-tazobactam         2,051           32                \>64   ≤0.5 to \>64     44.2                                      2,186   64      \>64    ≤0.25 to \>64    25.2
                             Tetracycline                    2,051           \>8               \>8    ≤0.25 to \>8     40.1                                      2,186   4       \>8     ≤0.25 to \>8     NA
                             Tigecycline                     2,051           1                 2      0.06 to 16       92.0[^*a*^](#T3F1){ref-type="table-fn"}   2,186   0.5     2       0.06 to 16       51.7[^*b*^](#T3F2){ref-type="table-fn"}
                             Trimethoprim-sulfamethoxazole   1,656           \>4               \>4    ≤0.06 to \>4     37.6                                      1,614   \>4     \>4     ≤0.06 to \>4     45.9
  *Klebsiella* spp.          Eravacycline                    801             0.5               2      0.06 to 16       72.4                                      943     0.5     1       0.06 to 16       77.0
                             Amikacin                        626             2                 16     ≤0.25 to \>64    92.0                                      667     2       16      ≤0.25 to \>64    88.6
                             Aztreonam                       801             \>16              \>16   ≤0.5 to \>16     8.6                                       943     \>16    \>16    ≤0.03 to \>16    3.4
                             Cefepime                        801             \>16              \>16   ≤0.25 to \>16    33.0                                      943     8       \>16    0.015 to \>16    37.7
                             Cefotaxime                      626             \>64              \>64   ≤0.015 to \>64   10.4                                      667     \>64    \>64    ≤0.015 to \>64   7.2
                             Ceftazidime                     801             \>16              \>16   ≤0.5 to \>16     19.5                                      943     \>16    \>128   ≤0.03 to \>128   10.1
                             Ceftriaxone                     801             \>4               \>4    ≤0.5 to \>4      6.9                                       943     \>4     \>32    0.03 to \>32     3.7
                             Colistin                        175             1                 1      0.25 to \>4      NA                                        276     0.5     1       0.25 to \>4      94.2
                             Ertapenem                       626             0.25              \>2    0.008 to \>2     72.2                                      667     0.25    \>2     0.008 to \>2     73.3
                             Gentamicin                      801             1                 \>8    ≤0.25 to \>8     57.4                                      943     1       \>16    ≤0.12 to \>16    62.1
                             Imipenem                        175             1                 \>8    ≤0.25 to \>8     68.0                                      276     1       8       ≤0.25 to \>8     86.2
                             Levofloxacin                    801             4                 \>4    ≤0.25 to \>4     32.6                                      943     1       \>8     0.03 to \>8      43.9
                             Meropenem                       626             0.06              \>4    0.015 to \>4     82.1                                      667     0.06    \>4     0.015 to \>4     84.4
                             Minocycline                     438             4                 \>16   0.25 to \>16     50.7                                      484     4       \>16    0.25 to \>16     NA
                             Piperacillin-tazobactam         801             64                \>64   ≤0.5 to \>64     31.0                                      943     64      \>128   0.5 to \>128     17.1
                             Tetracycline                    801             8                 \>8    ≤0.25 to \>8     46.2                                      943     4       \>64    ≤0.25 to \>64    NA
                             Tigecycline                     801             1                 4      0.12 to 16       89.5                                      943     1       2       0.12 to 16       38.7
                             Trimethoprim-sulfamethoxazole   626             \>4               \>4    ≤0.06 to \>4     35.9                                      667     \>4     \>4     ≤0.06 to \>4     42.9
  *Enterobacter* spp.        Eravacycline                    448             0.5               2      0.12 to 8        73.4                                      529     0.5     2       0.12 to 8        78.5
                             Amikacin                        364             1                 4      ≤0.25 to \>64    97.8                                      381     1       4       ≤0.25 to \>64    96.1
                             Aztreonam                       448             \>16              \>16   ≤0.5 to \>16     10.0                                      529     \>16    \>16    0.06 to \>16     1.9
                             Cefepime                        448             4                 \>16   ≤0.25 to \>16    43.3                                      529     4       \>16    0.06 to \>16     31.2
                             Cefotaxime                      364             \>64              \>64   0.06 to \>64     6.6                                       381     \>64    \>64    0.12 to \>64     0.5
                             Ceftazidime                     448             \>16              \>16   ≤0.5 to \>16     9.8                                       529     64      \>128   0.25 to \>128    1.0
                             Ceftriaxone                     448             \>4               \>4    ≤0.5 to \>4      6.0                                       529     \>4     \>32    0.5 to \>32      0.6
                             Colistin                        84              0.5               1      ≤0.12 to 2       NA                                        148     0.5     1       ≤0.12 to \>4     95.3
                             Ertapenem                       364             0.5               \>2    0.015 to \>2     56.0                                      381     0.5     \>2     0.015 to \>2     54.1
                             Gentamicin                      448             0.5               \>8    ≤0.25 to \>8     65.2                                      529     0.5     \>16    ≤0.12 to \>16    69.0
                             Imipenem                        84              1                 8      ≤0.25 to \>8     75.0                                      148     0.5     2       ≤0.25 to \>8     91.9
                             Levofloxacin                    448             0.5               \>4    ≤0.25 to \>4     54.5                                      529     0.25    8       0.008 to \>8     63.5
                             Meropenem                       364             0.12              0.5    0.015 to \>4     94.2                                      381     0.12    0.5     0.015 to \>4     95.8
                             Minocycline                     227             4                 \>16   1 to \>16        62.1                                      272     4       \>16    1 to \>16        NA
                             Piperacillin-tazobactam         448             64                \>64   ≤0.5 to \>64     31.3                                      529     64      \>128   ≤0.5 to \>128    13.0
                             Tetracycline                    448             4                 \>8    1 to \>8         50.7                                      529     4       \>64    0.5 to \>64      NA
                             Tigecycline                     448             1                 4      0.12 to 8        87.5                                      529     1       4       0.12 to 8        42.3
                             Trimethoprim-sulfamethoxazole   364             4                 \>4    ≤0.06 to \>4     49.7                                      381     0.5     \>4     ≤0.06 to \>4     59.6
  *Citrobacter* spp.         Eravacycline                    247             0.25              1      0.06 to 4        80.2                                      282     0.25    1       0.06 to 4        81.9
                             Amikacin                        210             1                 8      ≤0.25 to \>64    98.1                                      222     1       4       ≤0.25 to \>64    95.1
                             Aztreonam                       247             \>16              \>16   ≤0.5 to \>16     18.6                                      282     \>16    \>16    0.06 to \>16     4.3
                             Cefepime                        247             2                 \>16   ≤0.25 to \>16    67.6                                      282     1       \>16    0.06 to \>16     51.4
                             Cefotaxime                      210             64                \>64   0.06 to \>64     13.3                                      222     64      \>64    0.12 to \>64     3.6
                             Ceftazidime                     247             \>16              \>16   ≤0.5 to \>16     15.4                                      282     128     \>128   0.5 to \>128     1.8
                             Ceftriaxone                     247             \>4               \>4    ≤0.5 to \>4      12.6                                      282     \>4     \>32    0.12 to \>32     3.9
                             Colistin                        37              1                 2      0.25 to \>4      NA                                        60      1       1       0.25 to \>4      96.7
                             Ertapenem                       210             0.25              2      0.004 to \>2     76.7                                      222     0.25    2       0.008 to \>2     77.5
                             Gentamicin                      247             0.5               \>8    ≤0.25 to \>8     72.5                                      282     0.5     \>16    ≤0.12 to \>16    78.0
                             Imipenem                        37              1                 8      ≤0.25 to \>8     62.2                                      60      1       2       ≤0.25 to \>8     91.7
                             Levofloxacin                    247             0.5               \>4    ≤0.25 to \>4     53.4                                      282     0.25    \>8     0.015 to \>8     60.6
                             Meropenem                       210             0.06              1      0.015 to \>4     91.9                                      222     0.06    1       0.015 to \>4     92.8
                             Minocycline                     139             8                 \>16   ≤0.12 to \>16    48.9                                      162     4       \>16    ≤0.12 to \>16    NA
                             Piperacillin-tazobactam         247             \>64              \>64   ≤0.5 to \>64     27.1                                      282     64      \>128   ≤0.25 to \>128   9.9
                             Tetracycline                    247             4                 \>8    ≤0.25 to \>8     53.9                                      282     2       \>64    ≤0.25 to \>64    NA
                             Tigecycline                     247             0.5               2      0.12 to 4        92.7                                      282     0.5     2       0.12 to 4        58.9
                             Trimethoprim-sulfamethoxazole   210             0.25              \>4    ≤0.06 to \>4     57.6                                      222     0.12    \>4     ≤0.06 to \>4     67.1
  E. coli                    Eravacycline                    555             0.25              0.5    0.03 to 2        98.0                                      432     0.25    0.5     0.06 to 2        97.5
                             Amikacin                        456             2                 8      ≤0.25 to \>64    99.1                                      344     2       8       0.5 to \>64      94.5
                             Aztreonam                       555             16                \>16   ≤0.5 to \>16     39.1                                      432     \>16    \>16    ≤0.03 to \>16    18.8
                             Cefepime                        555             8                 \>16   ≤0.25 to \>16    43.1                                      432     16      \>16    0.015 to \>16    24.5
                             Cefotaxime                      456             \>64              \>64   ≤0.015 to \>64   37.9                                      344     \>64    \>64    ≤0.015 to \>64   21.2
                             Ceftazidime                     555             8                 \>16   ≤0.5 to \>16     46.9                                      432     16      64      0.06 to \>128    21.1
                             Ceftriaxone                     555             \>4               \>4    ≤0.5 to \>4      34.1                                      432     \>4     \>32    ≤0.015 to \>32   18.8
                             Colistin                        99              0.5               1      0.25 to 2        NA                                        88      0.5     1       0.25 to 4        96.6
                             Ertapenem                       456             0.015             0.25   0.004 to \>2     95.8                                      344     0.03    0.25    0.004 to \>2     94.5
                             Gentamicin                      555             8                 \>8    ≤0.25 to \>8     48.8                                      432     \>8     \>16    0.25 to \>16     43.1
                             Imipenem                        99              ≤0.25             1      ≤0.25 to 2       96.0                                      88      ≤0.25   1       ≤0.25 to 2       100.0
                             Levofloxacin                    555             \>4               \>4    ≤0.25 to \>4     13.9                                      432     8       \>8     0.03 to \>8      6.3
                             Meropenem                       456             0.03              0.06   ≤0.004 to 2      99.1                                      344     0.03    0.06    ≤0.004 to 2      100.0
                             Minocycline                     308             2                 16     0.25 to \>16     69.5                                      248     2       16      0.25 to \>16     NA
                             Piperacillin-tazobactam         555             4                 64     ≤0.5 to \>64     81.3                                      432     4       \>64    ≤0.25 to \>128   67.8
                             Tetracycline                    555             \>8               \>8    0.5 to \>8       16.8                                      432     64      \>64    0.5 to \>64      NA
                             Tigecycline                     555             0.25              1      0.06 to 4        98.9                                      432     0.25    1       0.06 to 4        87.0
                             Trimethoprim-sulfamethoxazole   456             \>4               \>4    ≤0.06 to \>4     20.8                                      344     \>4     \>4     ≤0.06 to \>4     23.0
  P. mirabilis               Eravacycline                    328             2                 4      0.25 to \>16     7.9                                       191     2       4       0.25 to \>16     6.3
                             Amikacin                        241             2                 16     0.5 to \>64      91.3                                      128     2       \>64    0.5 to \>64      79.7
                             Aztreonam                       328             ≤0.5              4      ≤0.5 to \>16     94.8                                      191     ≤0.5    4       ≤0.03 to \>16    67.5
                             Cefepime                        328             ≤0.25             16     ≤0.25 to \>16    77.7                                      191     1       \>16    0.03 to \>16     53.4
                             Cefotaxime                      241             0.03              \>64   ≤0.015 to \>64   61.0                                      128     32      \>64    ≤0.015 to \>64   35.9
                             Ceftazidime                     328             ≤0.5              \>16   ≤0.5 to \>16     78.1                                      191     1       32      ≤0.03 to \>128   53.9
                             Ceftriaxone                     328             ≤0.5              \>4    ≤0.5 to \>4      62.5                                      191     4       16      ≤0.015 to \>32   43.5
                             Colistin                        87              \>4               \>4    \>4 to \>4       NA                                        63      \>4     \>4     \>4 to \>4       0.0
                             Ertapenem                       241             0.015             0.03   0.004 to \>2     98.8                                      128     0.015   0.06    0.004 to \>2     97.7
                             Gentamicin                      328             8                 \>8    ≤0.25 to \>8     48.8                                      191     \>8     \>16    0.25 to \>16     15.7
                             Imipenem                        87              4                 8      ≤0.25 to \>8     8.1                                       63      4       8       ≤0.25 to \>8     NA[^*b*^](#T3F2){ref-type="table-fn"}
                             Levofloxacin                    328             \>4               \>4    ≤0.25 to \>4     11.0                                      191     \>4     \>8     0.03 to \>8      5.8
                             Meropenem                       241             0.06              0.12   0.015 to \>4     99.2                                      128     0.06    0.25    0.015 to \>4     98.4
                             Minocycline                     167             16                \>16   8 to \>16        0.0                                       93      \>16    \>16    8 to \>16        NA
                             Piperacillin-tazobactam         328             ≤0.5              8      ≤0.5 to \>64     95.4                                      191     1       8       ≤0.25 to \>128   90.6
                             Tetracycline                    328             \>8               \>8    1 to \>8         0.6                                       191     32      \>64    1 to \>64        NA
                             Tigecycline                     328             4                 8      0.25 to \>32     21.0                                      191     4       8       0.25 to \>32     1.1
                             Trimethoprim-sulfamethoxazole   241             \>4               \>4    ≤0.06 to \>4     7.1                                       128     \>4     \>4     ≤0.06 to \>4     7.0
  S. marcescens              Eravacycline                    87              2                 4      0.5 to 8         4.6                                       85      2       4       0.5 to 8         5.9
                             Amikacin                        54              2                 16     1 to \>64        90.7                                      38      4       32      1 to \>64        79.0
                             Aztreonam                       87              16                \>16   ≤0.5 to \>16     36.8                                      85      16      \>16    ≤0.5 to \>16     7.1
                             Cefepime                        87              2                 \>16   ≤0.25 to \>16    54.0                                      85      2       \>16    ≤0.25 to \>16    41.2
                             Cefotaxime                      54              32                \>64   0.25 to \>64     25.9                                      38      64      \>64    0.5 to \>64      2.6
                             Ceftazidime                     87              4                 \>16   ≤0.5 to \>16     58.6                                      85      4       32      0.25 to \>128    34.1
                             Ceftriaxone                     87              \>4               \>4    ≤0.5 to \>4      20.7                                      85      \>4     \>32    1 to \>32        2.4
                             Colistin                        33              \>4               \>4    1 to \>4         NA                                        47      \>4     \>4     1 to \>4         6.4
                             Ertapenem                       54              0.12              \>2    0.015 to \>2     72.2                                      38      0.25    \>2     0.03 to \>2      63.2
                             Gentamicin                      87              2                 \>8    ≤0.25 to \>8     60.9                                      85      2       \>16    ≤0.12 to \>16    52.9
                             Imipenem                        33              1                 4      ≤0.25 to \>8     75.8                                      47      1       2       ≤0.25 to \>8     91.5
                             Levofloxacin                    87              2                 \>4    ≤0.25 to \>4     26.4                                      85      2       8       0.06 to \>8      30.6
                             Meropenem                       54              0.12              \>4    0.008 to \>4     83.3                                      38      0.12    \>4     0.03 to \>4      79.0
                             Minocycline                     17              4                 16     2 to \>16        52.9                                      18      4       16      2 to \>16        NA
                             Piperacillin-tazobactam         87              16                \>64   1 to \>64        52.9                                      85      32      \>128   2 to \>128       25.9
                             Tetracycline                    87              \>8               \>8    4 to \>8         3.5                                       85      \>8     32      4 to \>64        NA
                             Tigecycline                     87              2                 4      0.5 to 8         77.0                                      85      2       4       0.5 to 4         1.2
                             Trimethoprim-sulfamethoxazole   54              2                 \>4    0.12 to \>4      50.0                                      38      4       \>4     0.12 to \>4      44.7
  A. baumannii               Eravacycline                    1,502           0.5               2      0.03 to 16       NA                                        1,271   0.5     2       0.06 to 16       NA
                             Amikacin                        1,130           \>64              \>64   0.12 to \>64     27.8                                      1,007   \>64    \>64    0.12 to \>64     17.8
                             Ampicillin-sulbactam            1,130           64                \>64   1 to \>64        7.3                                       1,007   64      \>64    2 to \>64        NA
                             Aztreonam                       1,502           \>16              \>16   0.25 to \>16     NA                                        1,271   \>64    \>64    8 to \>64        NA
                             Cefepime                        1,502           \>16              \>16   ≤0.25 to \>16    3.4                                       1,271   64      \>64    2 to \>64        NA
                             Ceftazidime                     1,502           \>16              \>16   ≤0.5 to \>16     4.4                                       1,271   \>64    \>64    2 to \>64        NA
                             Ceftriaxone                     1,502           \>32              \>32   1 to \>32        0.9                                       1,271   \>64    \>64    8 to \>64        NA
                             Colistin                        1,502           0.5               2      ≤0.03 to \>4     NA                                        1,271   0.5     2       0.12 to \>32     92.5
                             Gentamicin                      1,502           \>8               \>8    ≤0.03 to \>8     17.6                                      1,271   \>64    \>64    0.06 to \>64     8.9
                             Imipenem                        372             \>8               \>8    0.5 to \>8       15.9                                      264     \>8     \>8     8 to \>8         0.0
                             Levofloxacin                    1,502           \>4               \>4    ≤0.25 to \>4     2.4                                       1,271   16      \>64    0.06 to \>64     0.1
                             Meropenem                       1,130           64                \>64   0.06 to \>64     7.9                                       1,007   64      \>64    0.5 to \>64      4.7
                             Minocycline                     1,130           4                 16     ≤0.03 to \>64    54.0                                      1,007   4       16      ≤0.03 to \>64    NA
                             Piperacillin-tazobactam         1,502           \>64              \>64   ≤0.5 to \>64     1.8                                       1,271   \>128   \>128   2 to \>128       NA
                             Tetracycline                    1,502           \>8               \>8    0.5 to \>8       4.5                                       1,271   \>64    \>64    2 to \>64        NA
                             Tigecycline                     1,502           4                 8      0.25 to \>16     NA                                        1,271   4       8       0.25 to \>16     NA
                             Trimethoprim-sulfamethoxazole   1,130           64                \>64   ≤0.03 to \>64    15.8                                      1,007   64      \>64    0.06 to \>64     11.1

![](AAC.01699-19-t0003)

U.S. Food and Drug Administration (FDA) MIC interpretative breakpoints for *Enterobacteriaceae* for eravacycline (susceptible, ≤0.5 μg/ml) and tigecycline (susceptible, ≤2 μg/ml; intermediate, 4 μg/ml; resistant, ≥8 μg/ml) ([@B20]) were used in place of CLSI MIC breakpoints, as none currently exist. The 2019 EUCAST MIC interpretative breakpoints for tigecycline (susceptible, ≤0.5 μg/ml; resistant, ≥1 μg/ml) ([@B19]) are different from the FDA MIC breakpoints.

The MIC panel range is not low enough for *Proteeae* for 2019 EUCAST breakpoints.

NA, MIC breakpoint not available.

With regard to the comparator agents tested, the rate of susceptibility among the *Enterobacteriaceae* by the use of CLSI criteria was the highest for amikacin (99.1%), tigecycline (96.8%), the carbapenems meropenem (97.9%) and ertapenem (94.2%), and gentamicin (91.2%) ([Table 2](#T2){ref-type="table"}). Similar susceptibility was observed using EUCAST guidelines, with exceptions existing, such as for minocycline and tetracycline, for which no EUCAST breakpoints are given, and for colistin (99.4% susceptible by the use of EUCAST breakpoints), for which CLSI breakpoints are not given. Also, by use of the EUCAST criteria, tigecycline susceptibility was reduced to 70.6%, whereas eravacycline susceptibility remained at 92.6%. Other *Enterobacterales*, P. mirabilis, and S. marcescens were distinct, with reduced susceptibility to the tetracycline class, especially when susceptibility was evaluated using EUCAST breakpoints ([Table 2](#T2){ref-type="table"}). Among the *Enterobacteriaceae*, 19.5% (*n* = 2,051) were defined as being MDR isolates using CLSI breakpoints and 20.8% (*n* = 2,186) were defined as being MDR isolates using EUCAST breakpoints. The rates of susceptibility to all other comparators except amikacin, colistin (EUCAST breakpoints only), ertapenem, gentamicin (EUCAST breakpoints only), imipenem, meropenem, and tigecycline (CLSI breakpoints only) were less than 60% for the MDR isolate population. These susceptibilities are similar to those seen in other global surveillance studies ([@B19], [@B20]).

In addition to the *Enterobacterales*, a large collection of Gram-negative nonfermenters was tested, including A. baumannii (*n* = 2,097) and S. maltophilia (*n* = 1,210). For A. baumannii, high rates of resistance to the majority of the comparators were seen, with the levels of susceptibility to colistin (95.1%) and minocycline (67.3%) being the highest. Among the few agents with a breakpoint for S. maltophilia, the rate of susceptibility to minocycline was the highest at 99.0%. Approximately 24% and 15.7% of the isolates were resistant to levofloxacin and trimethoprim-sulfamethoxazole, respectively, similar to the findings of a surveillance study looking at isolates from 1998 to 2008 in Taiwan ([@B21]).

In this surveillance study, eravacycline demonstrated improved potency, based on MIC~90~ values, over tigecycline, showing a 4-fold greater potency than tigecycline against populations of A. baumannii, *Klebsiella* spp., and P. mirabilis and a 2-fold greater potency against E. coli, *Enterobacter* spp., *Citrobacter* spp., and S. maltophilia. Eravacycline and tigecycline showed equivalent potency against S. marcescens. Previous *in vitro* studies comparing eravacycline and tigecycline have reported similar 2- to 4-fold improvements in the MIC~90~ values of eravacycline over those of tigecycline ([@B7], [@B12], [@B13], [@B16], [@B22][@B23][@B26]). The tigecycline MIC~90~s for *Enterobacterales* spp., A. baumannii, and S. maltophilia determined in this study were equivalent to the MIC~90~s of tigecycline determined in other global surveillance studies ([@B27], [@B28]).

In addition to greater potency, eravacycline presents additional potential advantages over tigecycline: higher concentrations in serum and tissue (especially in the lung) and improved tolerability ([@B7], [@B29][@B30][@B31]). Previous studies have demonstrated that the *in vitro* activity of eravacycline is not affected by the presence of many of the resistance mechanisms likely present in the current surveillance population. These include studies which looked at the *in vitro* activity of eravacycline against ESBL-producing isolates of E. coli and K. pneumoniae; fluoroquinolone-susceptible and fluoroquinolone-resistant isolates of E. coli (including those of the MDR sequence type 131 genotype); polymyxin-resistant (*mcr-1*-positive) *Enterobacteriaceae*; carbapenem-resistant *Enterobacteriaceae*, including KPC-, SME-, VIM-, IMP-, NDM-, and OXA-48-producing isolates; and MDR *Enterobacteriaceae* and A. baumannii ([@B12], [@B13], [@B16], [@B22][@B23][@B24], [@B26]).

Eravacycline is currently approved for use by both EMA and FDA for the treatment of complicated intra-abdominal infections. As previously described, eravacycline maintains an overall potency advantage over tigecycline across approved organisms. The adoption of restrictive breakpoint criteria for tigecycline and eravacycline in the EUCAST 2019 guidelines, in contrast to the broad, albeit decade-old, tigecycline breakpoints granted by the FDA, makes comparisons of susceptibility between the two agents difficult. While the FDA breakpoints for both agents are granted for *Enterobacteriaceae*, the clinical efficacy of eravacycline against E. coli, Enterobacter cloacae, Citrobacter freundii, and species of *Klebsiella* is noted. Current eravacycline breakpoints from EUCAST were published concurrently with a reduction in both the tigecycline breakpoint and the approved organism list. The disconnect between approved interpretative criteria and organism coverage for tigecycline and other agents across these regulatory agencies highlights the need for greater efforts toward the harmonization of breakpoints.

Treatment of complicated intra-abdominal infection (cIAI) involves a combination of surgery and empirical antimicrobial therapy. Antimicrobial therapy must be sufficient to encompass a wide range of pathogens, including Gram-positive and Gram-negative aerobic and anaerobic bacteria ([@B32][@B33][@B34]). In cIAI patients, the most commonly encountered Gram-negative pathogens include E. coli, *Klebsiella* spp., and *Enterobacter* spp. ([@B35]). A. baumannii is less common in cIAI infections but has been noted to be an increasing cause of postoperative infections in hospital settings ([@B36][@B37][@B38]).

Eravacycline demonstrated potent *in vitro* activity against the clinically important Gram-negative organisms associated with cIAIs in humans. For all organisms, including A. baumannii and S. maltophilia, the MIC~90~s of eravacycline were 2- to 4-fold lower than those of tigecycline. This global surveillance investigation highlights the broad-spectrum potency of eravacycline against Gram-negative bacteria, including MDR strains, and further underscores its potential benefit for the treatment of cIAIs and other polymicrobial infections caused by resistant pathogens.

MATERIALS AND METHODS {#s3}
=====================

Bacterial isolates. {#s3.1}
-------------------

From 2013 through 2017, clinical isolates of *Enterobacterales* (*n* = 13,983), A. baumannii (*n* = 2,097), P. aeruginosa (*n* = 1,647), and S. maltophilia (*n* = 1,210) were collected by laboratories in 36 countries (in the Asia-Pacific region, Australia, Hong Kong, Japan, South Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, and Vietnam; in Europe, Austria, Belgium, Croatia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom; and in North America \[the United States\]). In the Asia-Pacific region, isolates were collected only in 2015 through 2017, and some other countries also did not participate in all years.

Table S1 in the supplemental material summarizes the numbers of isolates of *Enterobacteriaceae*, A. baumannii, and S. maltophilia collected by geographic region. For the *Enterobacteriaceae* and A. baumannii, approximately 40 to 45% of the isolates came from North America and Europe and 15% came from the Asia-Pacific region. For S. maltophilia, approximately 50% of the isolates came from Europe, 30% came from North America, and 20% came from the Asia-Pacific region. In total, there were 6,559, 5,667, 5,305, and 1,406 isolates, respectively, from respiratory, intra-abdominal, urinary, and other specimen sources.

The identity of each isolate was confirmed using matrix-assisted laser desorption ionization--time of flight (MALDI-TOF) mass spectrometry (Bruker Biotyper; Bruker Daltonics, Bremen, Germany). Isolates were limited to one per patient, determined by the participating laboratory algorithms to be clinically significant, and collected irrespective of their antimicrobial susceptibility profile and independently of patient gender or age. The study was not designed to directly compare the prevalence of antimicrobial-resistant pathogens across specific geographic locations but, rather, was designed to evaluate the *in vitro* activities of eravacycline and comparator antimicrobial agents against a global collection of frequently encountered clinical isolates of Gram-negative bacilli collected from 2013 to 2017.

Antimicrobial susceptibility testing. {#s3.2}
-------------------------------------

The *in vitro* susceptibilities of isolates were determined using the CLSI-defined broth microdilution method in 96-well broth microdilution panels ([@B17], [@B39]). The antimicrobial agents used in panel production were acquired as laboratory-grade powders from their respective manufacturers or from a commercial source. The list of antimicrobial agents tested in each of the four study periods varied slightly, in that some agents, in addition to those tested in the 2013 to 2014 period, were included in the 2015 to 2017 testing periods. Ten antimicrobial agents (aztreonam, cefepime, ceftazidime, ceftriaxone, eravacycline, gentamicin, levofloxacin, piperacillin-tazobactam, tetracycline, and tigecycline) were tested against all isolates in each study period from 2013 to 2017. Of note, imipenem was tested in 2013 and 2014, while ertapenem and meropenem were tested in 2015 to 2017; colistin was tested against *Enterobacteriaceae* only in 2013 and 2014; amoxicillin-clavulanate was tested only in 2015; ampicillin-sulbactam was tested only in 2015 and 2016; and cefotaxime, minocycline, and trimethoprim-sulfamethoxazole were tested only in 2015 to 2017. The eravacycline MICs for Gram-negative bacilli were read following the current CLSI standard for dilution method testing; MIC endpoints were read following panel incubation at 35°C in ambient air for 16 to 20 h (*Enterobacteriaceae*, P. aeruginosa) or 20 to 24 h (A. baumannii, S. maltophilia) ([@B17]). Quality control testing for eravacycline and other antimicrobial agents was performed on each day of testing as specified by the CLSI ([@B39]) using the CLSI-defined control strains E. coli ATCC 25922 and P. aeruginosa ATCC 27853.

MICs were interpreted using 2019 CLSI MIC breakpoints ([@B17]) and 2019 EUCAST MIC breakpoints ([@B18]), with the following exceptions: FDA MIC interpretative breakpoints for eravacycline and tigecycline ([@B29]) were used in place of CLSI MIC breakpoints, which are not currently published for these agents. Additionally, tigecycline breakpoints were lowered with the 2019 EUCAST MIC guidelines, while simultaneously, the label was restricted to E. coli and Citrobacter koseri from the *Enterobacteriaceae*; in order to perform a more accurate and complete comparison between eravacycline and tigecycline susceptibilities, the current breakpoints for both eravacycline and tigecycline were applied to susceptibility percentages for all *Enterobacteriaceae* species.

An MDR phenotype was defined as resistance to one or more agents from three or more antimicrobial agent classes recommended for testing for a specific pathogen or pathogen family (*Enterobacteriaceae*) and possessing MIC interpretative breakpoints published by CLSI ([@B17]) or EUCAST ([@B18]). Eravacycline and tigecycline were excluded from the list of agents used for the MDR determination. Because the list of antimicrobial agents tested in each study year varied slightly, the identified MDR populations also varied slightly in each study year. Identification of MDR isolates of S. maltophilia was excluded from the analysis because of the very limited number of antimicrobial agents with either CLSI ([@B17]) or EUCAST ([@B18]) MIC breakpoints for that species. Resistance to levofloxacin and trimethoprim-sulfamethoxazole was captured for this organism, as these represent the current treatment of choice and a proposed alternative, respectively ([@B40]).
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